Dementia with Lewy bodies (DLB) is pathologically characterized by the presence of ␣-synuclein-containing
Introduction
Up to 20% of elderly patients have dementia with Lewy Bodies (DLB) (Harding et al., 2002) . DLB exhibits clinical, pathological, and genetic features that overlap with both Alzheimer's disease (AD) and Parkinson's disease (PD) (Doubleday et al., 2002) . Like AD, most DLB cases are pathologically characterized by the presence of cortical amyloid deposition (Dickson et al., 1989; Lippa et al., 1994; Gomez-Isla et al., 1999) . In addition to A␤ plaques, DLB is typically characterized by the presence of Lewy bodies (LBs) within the neocortical, limbic, and paralimbic regions (GomezIsla et al., 1999; Gomez-Tortosa et al., 2000; Del Ser et al., 2001) . LBs are intracytoplasmic, eosinophilic, neuronal inclusions , mainly composed of aggregates of misfolded ␣-synuclein and ubiquitin in a ␤-sheet conformation (Levine, 1995) . Although LBs are commonly associated with DLB and PD, LBs have also been detected in sporadic and familial AD cases, most commonly sited within the amygdala (Lippa et al., 1998; Hamilton, 2000) .
Considerable effort is focused on biomarkers for the early diagnosis of neurodegenerative diseases such as AD. Significant progress has been made in targeting amyloid with radioligands based on derivatives of histological dyes for positron emission tomography (PET) Villemagne et al., 2005a) . As novel anti-amyloid therapeutics are evaluated, the development of a reliable method permitting early detection of amyloid deposition, even at presymptomatic stages, is highly desirable .
Pittsburgh compound B [PIB; also known as 6-OH-BTA-1 and 2-(4Ј-methylaminophenyl)-6-hydroxybenzothiazole] is a well characterized derivative of the amyloid-binding dye thioflavin-T (ThT) (LeVine, 1999) . PIB binds to A␤ and A␤ 1-42 fibrils with higher affinity than ThT and readily enters the rodent brain, showing high affinity for amyloid deposits (Klunk et al., 2001 Mathis et al., 2003) . In vitro, [ 3 H]-PIB binds to AD brain homogenates with high affinity; both plaques and cerebral amyloid angiopathy are selectively labeled by [
3 H]-PIB in AD brains (Klunk et al., 2001 ; Mathis et al., 2002 Mathis et al., , 2003 . Carbon-11-labeled PIB ([ 11 C]-PIB) is a suitable biomarker for the in vivo quantitation of cerebral amyloid, demonstrating a robust differ-ence in the retention pattern between AD and healthy subjects (Klunk et al., 2004; Rowe et al., 2007) ; AD cases having significantly higher retention of [
11 C]-PIB in brain cortical areas (Klunk et al., 2004; Buckner et al., 2005; Rowe et al., 2007) .
We used [ 11 C]-PIB PET for the evaluation of AD and DLB subjects (Villemagne et al., 2005b; Rowe et al., 2007) . All AD subjects showed marked cortical and subcortical [
11 C]-PIB binding. Most DLB subjects exhibited high [
11 C]-PIB binding with a similar distribution to AD; however, the degree of retention was generally lower. Because ThT binds both aggregated A␤ and ␣-synuclein (Chauhan et al., 1997; Conway et al., 2000) , it is plausible that [ 11 C]-PIB brain retention in DLB patients could be attributable to binding to ␣-synuclein-containing LBs, instead of or in addition to A␤ plaques. To establish the contribution of ␣-synuclein/Lewy bodies to PIB binding in [
11 C]-PIB PET studies, we characterized the in vitro binding of [ 3 H]-PIB to recombinant human ␣-synuclein and amyloid-containing and amyloid-free DLB brain homogenates.
Materials and Methods
Chemicals. All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise stated. [
3 H]-PIB (Ͼ97% purity) was sourced from American Radiolabeled Chemicals (St. Louis, MO) (specific activity, 2679 GBq/mmol). Unlabeled PIB was synthesized as described previously . Human A␤ 1-42 was purchased from the W. M. Keck Laboratory (Yale University, New Haven, CT).
Tissue collection and characterization. Brain tissue was collected at autopsy. The sourcing and preparation of the human brain tissue was conducted by the National Neural Tissue Resource Centre. AD pathological diagnosis was made according to standard The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease (1997) criteria. DLB cases were diagnosed using consensus guidelines (McKeith et al., 1996) and classified as either DLB-A␤ [DLB subject with evidence of neuritic plaques and/or cerebral vascular amyloid, as determined by immunohistochemistry (IHC) and ELISA] or pure DLB (no significant evidence of neuritic plaques and/or cerebral vascular amyloid). Determination of age-matched control cases were subject to the above criteria. The number of subject cases used is indicated in the figure/table legends.
Overall, 12 AD, five DLB-A␤, one pure DLB, and 13 age-matched control subjects were used in this study.
Preparation of amyloid fibrils. Synthetic A␤ 1-42 was dissolved in 1ϫ PBS, pH 7.7, to a final concentration of 200 M. Recombinant human ␣-synuclein was expressed and purified as described previously (LeVine, 1999; Cappai et al., 2005) and dissolved in 10 mM phosphate buffer, pH 7.4, to a final concentration of 200 M. These solutions were incubated at , respectively. B, Scatchard analysis identified two classes of PIB-binding sites on ␣-synuclein fibrils (K d1 and B max1 of 10.07 nM and 2.87 pmol of PIB/nmol of ␣-synuclein, respectively; K d2 and B max2 of 88.49 nM and 9.54 pmol of PIB/nmol of ␣-synuclein, respectively). Binding data were analyzed using GraphPad Prism (version 1.0). The figure is representative of at least three independent experiments. or 7 d for ␣-synuclein, with agitation (220 rpm; orbital mixer incubator. After aggregation, ϳ5% of the protein remained in the supernatant after centrifugation at 12,000 ϫ g for 20 min. Fibril aggregation was confirmed through ThT fluorescence spectroscopy and electron microscopy (EM). Thioflavin-T fluorescence spectroscopy. ThT fluorescence was measured using a Varian (Palo Alto, CA) fluorescence spectrophotometer (LeVine, 1999; Cappai et al., 2005) . Aliquots of 200 M A␤ 1-42 or ␣-synuclein were removed at regular time intervals and diluted in assay buffer (10 M ThT and 50 mM phosphate buffer, pH 7.4), and fluorescence measurements were taken at 444 nm (excitation) and 450 -550 nm (emission), with an integration time of 1 s.
Transmission EM. Fibril formation of A␤ 1-42 and ␣-synuclein was confirmed by transmission EM after staining with uranyl acetate. Carbon-coated copper EM grids were coated with ␣-synuclein or A␤ 1-42 fibrils, as described previously (Smith and Radford, 2001 ). Grids were viewed on a Siemens (Munich, Germany) 102 transmission electron microscope, operating at a voltage of 60 kV.
Preparation of human brain tissue for in vitro binding studies. Gray matter was isolated from postmortem frontal cortex tissue from AD, DLB-A␤, pure DLB, and age-matched control subjects. Isolated tissue was then homogenized in 1ϫ PBS (without calcium and magnesium), using an ultrasonic cell disrupter (twice for 30 s each at 24,000 rpm; Virsonic 600; VirTis, Gardiner, NY). Protein concentration was determined using the BCA protein assay (Pierce Biotechnology, Rockford, IL), and brain tissue homogenates were aliquoted and frozen at Ϫ80°C until used.
ELISA for A␤ detection. Brain (gray matter, frontal cortex) A␤ levels were determined using the DELFIA Double Capture ELISA as described by George et al. (2004) and Li et al. (2006) . Brain tissues were homogenized as described above. The homogenate was solubilized with guanidine HCl to a final concentration of 5 M followed by centrifugation at 16,000 ϫ g for 20 min. To measure A␤ 1-40 or A␤ 1-42 , supernatants were diluted 1:10 with blocking buffer (0.25% casein or Superblock in PBS with 0.025% Tween 20) before adding to the plate. Plates were coated with either G210 (for detection of A␤ 1-40 ) or G211 (for A␤ 1-42 ) monoclonal antibodies and then blocked with 0.5% (w/v) casein/PBS or Superblock/PBS buffer, pH 7.4. After washing the plates, WO2-Biotin was added to the wells. A␤ 1-40 and A␤ 1-42 peptide standards and samples were assayed in triplicate and incubated overnight at 4°C. The plates were washed, europium-labeled streptavidin was added, and the plates were then developed with enhancement solution. Analysis was performed using the Wallac Victor 1420 multilabel plate reader (PerkinElmer, Melbourne, Australia) with excitation at 340 nm and emission at 613 nm.
In 3 H]-PIB to human brain homogenates was assessed by incubating 100 g of brain homogenate from AD, DLB-A␤ (DLB containing A␤), pure DLB (A␤-free), and age-matched control subjects with increasing concentrations of [ 3 H]-PIB in the absence or presence of unlabeled PIB, as described above. Bound and free radioactivity were separated by filtration under reduced pressure (multiscreen HTS vacuum manifold; multiscreen HTS 96-well filtration plates; 0.65 m; Millipore, Billerica, MA). Filters were washed three times with 200 l of assay buffer and incubated overnight in 3 ml of scintillation fluid (Emulsifier Safe Scintillation mixture; PerkinElmer). Radioactivity was counted in a beta counter (LS6500 multipurpose scintillation counter; Beckman Coulter, Fullerton, CA). Binding data were analyzed with curve-fitting software (GraphPad Prism version 1.0; GraphPad Software, San Diego, CA). All experiments were conducted in triplicate.
IHC and fluorescence analysis. Brain tissue from AD and DLB-A␤ subjects was fixed in 10% formalin/PBS and embedded in paraffin. For immunohistochemistry, 5 m serial sections were deparaffinized and treated with 80% formic acid for 5 min, and endogenous peroxidase activity was blocked using 3% hydrogen peroxide. Sections were then treated with blocking buffer (20% fetal calf serum, 50 mM Tris-HCl, and 175 mM NaCl, pH 7.4) before incubation with primary antibodies to ␣-synuclein [97/8; 1:2000 dilution (Culvenor et al., 1999) ] or A␤ (1e8; 1:50), for 1 h at room temperature. Serial 5 m tissue sections were stained as follows: the first and third sections were immunostained with 97/8 or 1e8 antibodies to identify Lewy bodies or A␤ plaques, respectively. The second serial section was stained with unlabeled PIB to assess whether PIB staining colocalized with the immunodetected Lewy bodies and/or A␤ plaques. Visualization of antibody reactivity was achieved using the LSAB kit (labeled streptavidin-biotin; Dako, Australia, Botany, New South Wales, Australia), and sections were then incubated with hydrogen-peroxidase-diaminobenzidine (H 2 O 2 -DAB) to visualize the ␣-synuclein-or A␤-positive deposits. Sections were counterstained with Mayer's hematoxylin. To detect PIB fluorescence, quenching was first performed whereby sections were first deparaffinized and tissue Image quantification. Frontal (Brodmann region 9) and mesial temporal/hippocampus (Brodmann areas 20 and 28) brain tissue sections from AD and DLB-A␤ and age-matched control subjects were immunostained with 1e8 and 97/8 antibodies to identify A␤ plaques and Lewy bodies, respectively. A total of 140 brain images from five regions in each section were acquired using a Zeiss (Thornwood, NY) Axiocam HRc 12 megapixel color digital camera yielding ϳ300 high-resolution (ϳ1.2 pixel/ m), 24 bit red-green-blue (RGB) color images. Image quantification was then conducted using ImagePro Plus version 5.1 software (Media Cybernetics, Silver Spring, MD). For each image, a region of interest was drawn around the margins of the brain tissue under the field of view. A␤ or ␣-synuclein-positive structures were identified in all sections, and an automated method of color selection thresholding was used to separate either plaques or Lewy bodies from background tissue. A filter was also used to only include structures that were Ͼ10 pixels in size. Data were expressed as the percentage of the total area of each brain section that was either A␤-or ␣-synuclein-positive pixels. (␣-syn) ; B] antibodies to detect plaques or Lewy bodies within the temporal or frontal regions of AD, DLB, or age-matched control subjects, respectively. Images were acquired on a Zeiss Axioscop 50 microscope using a 5ϫ/0.15 Planeofluar objective. Images were digitized using a Zeiss Axiocam HRc 12 megapixel color digital camera and analyzed using ImagePro Plus 5.1 (Media Cybernetics). Image quantification analysis is described in Materials and Methods. Image quantification data are expressed as a fraction of the total brain area and presented in Table 4 . The above images are representative of a total of 300 high-resolution (ϳ1.2 pixels/m), 24 bit RGB color images analyzed. Scale bars, 50 m. spectively, as demonstrated by an increase in the ThT fluorescence ( Fig. 1 A, B, respectively) . Fibril formation was further confirmed by transmission EM after staining with uranyl acetate. The A␤ 1-42 and ␣-synuclein fibrils measured 6 -10 nm in diameter and were at least 100 nm in length (Fig. 1C,D, respectively) , consistent with previous studies (Harper et al., 1997; Walsh et al., 1997; Conway et al., 2000; Yong et al., 2002) .
Results

Characteristics of [ 3 H-]-PIB binding to recombinant
To determine the specificity of [ 3 H]-PIB for ␣-synuclein fibrils, in vitro saturation studies were conducted using equimolar concentrations (200 nM; ϳ4.0 ϫ 10 Ϫ11 mol) of either A␤ 1-42 or ␣-synuclein fibrils. Scatchard analysis identified two classes of binding sites in both types of fibrils investigated (Fig. 2) . Overall, the affinity of [ 3 H]-PIB for synthetic A␤ 1-42 fibrils was higher than that observed for ␣-synuclein fibrils; the K d of the high-(K d1 ) and low (K d2 )-affinity binding sites was 10-fold and fourfold lower in A␤ 1-42 fibrils than that observed for ␣-synuclein fibrils, respectively (Table 1) . Although not significant, B max values were relatively higher for ␣-synuclein fibrils, when compared with the A␤ 1-42 fibrils tested. Binding parameters of [ 3 H]-PIB for A␤ 1-42 fibrils were consistent with previous studies ).
In vitro [ 3 H]-PIB binding analysis of human AD and DLB brain
In previous studies, postmortem human brain homogenates have been extensively used to characterize amyloid imaging agents, including PIB and closely related benzothiazoles (Klunk et al., 1995 Mathis et al., 2003) . To further assess the potential contribution of [ 11 C]-PIB binding to Lewy bodies, we compared the in vitro kinetics of [ 3 H]-PIB binding to amyloidcontaining subjects (DLB-A␤ and AD) versus amyloid-free (nonsignificant detection of amyloid) subjects (pure DLB and age-matched control). A␤ ELISA analysis was used to establish the presence/absence (nonsignificant levels) of amyloid, before conducting binding studies (Table 2) (Fig. 3 A, B , respectively; Table 1 ). In contrast, [
3 H]-PIB did not significantly bind to amyloid-free DLB (DLBpure) (Fig. 3C) or age-matched control subjects (Fig. 3D) , and hence, no binding parameters could be calculated.
As previously noted, the determination of B max can be largely influenced by [ 3 H]-PIB binding at saturating concentrations (high nanomolar/low micromolar concentrations). To further ascertain the potential binding of PIB at low concentrations typically achieved during [
11 C]-PIB PET studies, the binding of 1 nM [
3 H]-PIB to the above-mentioned homogenates was analyzed. Binding of 1 nM [
3 H]-PIB was significantly detected in A␤-containing AD and DLB-A␤ brain homogenates (Table 3) . Conversely, "A␤-free" brain homogenates (pure DLB and agematched control subjects) showed very little [ 3 H]-PIB binding at the 1 nM concentration, compared with A␤-containing homogenates (Table 3 ). The quantity of [ 3 H]-PIB bound to AD subjects was ϳ40-fold and twofold higher than age-matched control and DLB-A␤ subjects, respectively. These data were consistent with the quantity of A␤ detected by ELISA (Table 2) .
PIB and immunohistochemical staining of human AD and DLB subjects As a qualitative measure of its potential binding to ␣-synuclein deposits by fluorescence microscopy, unlabeled PIB was used to stain fixed serial sections from the frontal cortex of AD and DLB subjects and detected by fluorescence microscopy (Fig. 4 A, B , respectively). Serial sections were immunostained for A␤ plaques and Lewy bodies with the anti-A␤ and ␣-synuclein antibodies, respectively. Although PIB staining colocalized with A␤ plaques identified in AD and DLB-A␤ brain sections (Fig. 4 A, B , respectively), PIB did not appear to colocalize with ␣-synucleinpositive Lewy bodies (arrows indicate location of Lewy bodies, identified by ␣-synuclein antibody, 97/8).
Image quantification of human AD and DLB subjects
To further ascertain the potential contribution of Lewy bodies to the [ 11 C]-PIB PET images, we quantified the relative area occupied by A␤ plaques and Lewy bodies within brain tissue sections [frontal cortex (Brodmann region 9) and mesial temporal/hippocampus (Brodmann region 20/28)] from AD, DLB-A␤, and age-matched control subjects. An example of the analysis undertaken is depicted in Figure 5 . Image quantification analysis indicated that within a subject group, the area occupied by A␤ plaques was similar in both brain regions investigated (Table 4) . Furthermore, the relative A␤ plaque area was twofold higher in AD compared with DLB subjects. Importantly, image quantification analysis in DLB-A␤ subjects indicated that A␤ plaques occupy 30 times the area of Lewy bodies (Table 4) .
Discussion
As new therapies are being developed to prevent or treat Alzheimer's disease (Cherny et al., 2001; DeMattos et al., 2001; Ritchie et al., 2003; Xia, 2003; Schenk et al., 2004; Masters et al., 2006) , there is a clear need to specifically quantify the A␤ load in vivo. This is becoming increasingly relevant because A␤ deposition is common to other forms of dementias, such as DLB (McKeith et al., 1996) . The ability to detect preclinical or early stage disease, combined with anti-A␤ amyloid therapy in the at-risk patient, may prevent or delay functional and irreversible cognitive losses, as well as allowing optimization and monitoring of treatment (Minger et al., 2000; Rogers et al., 2002; Mathis et al., 2003; Fox et al., 2005; Masters et al., 2006) .
[ 11 C]-PIB PET imaging provides quantitative information of amyloid deposits in living subjects (Klunk et al., 2004; Rowe et al., 2007) . However, there is limited knowledge regarding the selectivity of PIB for other amyloidogenic proteins; particularly because AD has been described as a "triple brain amyloidosis" (Trojanowski, 2002 ). The AD brain comprises different proteins (tau and ␣-synuclein) or peptide fragments (A␤) that fibrillize and aggregate into pathological deposits of amyloid within (neurofibrillary tangles and Lewy bodies) and outside (A␤ plaques) neurons (Trojanowski, 2002; Klunk et al., 2004) . It is critically important that the selectivity of PIB for these other misfolded proteins is established to avoid misinterpretation and incorrect Frontal and temporal/hippocampus (Temp/Hipp) regions (Brodmann areas 9 and 20/28, respectively) from 30 subjects were evaluated. From each subject, five brain regions were examined. For image analysis, 300 highresolution images were generated and digitized, identifying either A␤ plaques or Lewy bodies as the region of interest (ROI). The ROIs (A␤ plaques or Lewy bodies) are represented as a percentage of the total area examined.
diagnosis. The ability of PIB to bind to neurofibrillary tangles (NFTs) has been previously addressed, and PIB does not significantly bind to NFTs . The potential of PIB binding to ␣-synuclein is unknown. In a similar way to A␤, ThT binds to ␣-synuclein aggregates, suggesting that its derivative may also bind to Lewy bodies. Moreover, [ 11 C]-PIB retention within the cortical regions of DLB patients raised the possibility that the [ 11 C]-PIB PET signal may be attributable to the presence of Lewy bodies within these brain regions or may contribute to the overall PET signal (Villemagne et al., 2005b; Rowe et al., 2007) .
In agreement with previous studies, in vitro binding studies indicated that [ 3 H]-PIB bound significantly to A␤ 1-42 fibrils, exhibiting both high-and low-affinity binding sites (Fig. 2 A) ). Binding of [ 3 H]-PIB to ␣-synuclein fibrils was observed only at equimolar concentration to A␤ 1-42 fibrils (Fig. 2 B) . As PIB is a derivative of ThT, these findings are consistent with the use of ThT to monitor ␣-synuclein fibrillogenesis (Conway et al., 2000 Fig. 3 ). Despite the use of high specific activity [ 3 H]-PIB, we did not detect two classes of PIB binding sites in AD or DLB-A␤ homogenates; as previously reported in ϳ50% of the AD cases investigated . Nevertheless, similar K d values calculated for both AD and DLB-A␤ homogenates were indicative of a single/similar [ 3 H]-PIB binding site and also consistent with the high-affinity K d1 that has previously been reported . Interestingly, the B max values calculated for DLB-A␤ and AD brain homogenates did not correlate with total A␤ levels, as determined by ELISA; B max of DLB-A␤ was modestly higher than the B max of AD brain homogenates, despite ELISA A␤ levels being twofold higher in AD than in DLB-A␤ brain homogenates. Although A␤ plaques are primarily composed of A␤ and A␤ 1-42 , other species of A␤ (i.e., A␤ 1-39 and A␤ ) are also present in human brain and were not assessed by ELISA in this study (Katzman and Saitoh, 1991; Kerr and Small, 2005) . Although it is plausible that other untested A␤ species may have contributed to the B max , it should be noted that the determination of B max using saturating high nanomolar to low micromolar concentrations of [ 3 H]-PIB can result in spurious results. This later explanation for the above-mentioned discrepancy in B max / ELISA values seems highly likely because [ 3 H]-PIB binding at nonsaturating and low nanomolar concentration [1 nM (typically achieved in PET)] was consistent with A␤-ELISA data presented in this study (Table 3) .
The use of unlabeled PIB in fluorescence studies demonstrated that PIB staining [even at high concentrations (100 M)] does not appear to bind to Lewy bodies, given the absence of PIB colocalization with ␣-synuclein-positive Lewy bodies (Fig. 4) . Nevertheless, PIB staining of A␤ plaques was most evident.
Finally, image quantification analysis established that the contribution of Lewy bodies to the [ 11 C]-PIB PET signal may be negligible, because Lewy bodies occupy Ͻ0.1% of the DLB-A␤ brain areas investigated. In comparison, A␤ plaques occupy 35 times the area of the Lewy bodies, in the same DLB brains. Furthermore, given the overlapping pathology of AD and DLB-A␤, [
11 C]-PIB PET will be incapable of differentiating the two overlapping neurodegenerative diseases, without the assistance of clinical diagnosis.
In conclusion, this study supports the notion that [ 11 C]-PIB PET retention within the cortical gray matter regions of DLB patients (Villemagne et al., 2005b; Rowe et al., 2007) is largely attributable to the binding of [
11 C]-PIB to A␤ plaques and not to ␣-synuclein-containing Lewy bodies.
